Cargando…

Therapeutic potential of induced iron depletion using iron chelators in Covid-19

Ferritin, which includes twenty-four light and heavy chains in varying proportions in different tissues, is primarily responsible for maintaining the body's iron metabolism. Its normal value is between 10 and 200 ngmL(−1) in men and between 30 and 300 ngmL(−1) in women. Iron is delivered to the...

Descripción completa

Detalles Bibliográficos
Autores principales: Poonkuzhi Naseef, Punnoth, Elayadeth-Meethal, Muhammed, Mohammed Salim, K.T., Anjana, A, Muhas, C, Abdul Vajid, K., Saheer Kuruniyan, Mohamed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666385/
https://www.ncbi.nlm.nih.gov/pubmed/34924800
http://dx.doi.org/10.1016/j.sjbs.2021.11.061
_version_ 1784614197733097472
author Poonkuzhi Naseef, Punnoth
Elayadeth-Meethal, Muhammed
Mohammed Salim, K.T.
Anjana, A
Muhas, C
Abdul Vajid, K.
Saheer Kuruniyan, Mohamed
author_facet Poonkuzhi Naseef, Punnoth
Elayadeth-Meethal, Muhammed
Mohammed Salim, K.T.
Anjana, A
Muhas, C
Abdul Vajid, K.
Saheer Kuruniyan, Mohamed
author_sort Poonkuzhi Naseef, Punnoth
collection PubMed
description Ferritin, which includes twenty-four light and heavy chains in varying proportions in different tissues, is primarily responsible for maintaining the body's iron metabolism. Its normal value is between 10 and 200 ngmL(−1) in men and between 30 and 300 ngmL(−1) in women. Iron is delivered to the tissue via them, and they act as immunomodulators, signaling molecules, and inflammatory markers. When ferritin level exceeds 1000 µgL(-1), the patient is categorized as having hyperferritinemia. Iron chelators such as deferiprone, deferirox, and deferoxamine are currently FDA approved to treat iron overload. The inflammation cascade and poor prognosis of COVID-19 may be attributed to high ferritin levels. Critically ill patients can benefit from deferasirox, an iron chelator administered orally at 20–40 mgkg(−1) once daily, as well as intravenous deferoxamine at 1000 mg initially followed by 500 mg every 4 to 12 h. It can be combined with monoclonal antibodies, antioxidants, corticosteroids, and lactoferrin to make iron chelation therapy effective for COVID-19 victims. In this article, we analyze the antiviral and antifibrotic activity of iron chelators, thereby promoting iron depletion therapy as a potentially innovative treatment strategy for COVID-19.
format Online
Article
Text
id pubmed-8666385
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-86663852021-12-14 Therapeutic potential of induced iron depletion using iron chelators in Covid-19 Poonkuzhi Naseef, Punnoth Elayadeth-Meethal, Muhammed Mohammed Salim, K.T. Anjana, A Muhas, C Abdul Vajid, K. Saheer Kuruniyan, Mohamed Saudi J Biol Sci Review Ferritin, which includes twenty-four light and heavy chains in varying proportions in different tissues, is primarily responsible for maintaining the body's iron metabolism. Its normal value is between 10 and 200 ngmL(−1) in men and between 30 and 300 ngmL(−1) in women. Iron is delivered to the tissue via them, and they act as immunomodulators, signaling molecules, and inflammatory markers. When ferritin level exceeds 1000 µgL(-1), the patient is categorized as having hyperferritinemia. Iron chelators such as deferiprone, deferirox, and deferoxamine are currently FDA approved to treat iron overload. The inflammation cascade and poor prognosis of COVID-19 may be attributed to high ferritin levels. Critically ill patients can benefit from deferasirox, an iron chelator administered orally at 20–40 mgkg(−1) once daily, as well as intravenous deferoxamine at 1000 mg initially followed by 500 mg every 4 to 12 h. It can be combined with monoclonal antibodies, antioxidants, corticosteroids, and lactoferrin to make iron chelation therapy effective for COVID-19 victims. In this article, we analyze the antiviral and antifibrotic activity of iron chelators, thereby promoting iron depletion therapy as a potentially innovative treatment strategy for COVID-19. Elsevier 2022-04 2021-12-13 /pmc/articles/PMC8666385/ /pubmed/34924800 http://dx.doi.org/10.1016/j.sjbs.2021.11.061 Text en © 2021 The Author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Poonkuzhi Naseef, Punnoth
Elayadeth-Meethal, Muhammed
Mohammed Salim, K.T.
Anjana, A
Muhas, C
Abdul Vajid, K.
Saheer Kuruniyan, Mohamed
Therapeutic potential of induced iron depletion using iron chelators in Covid-19
title Therapeutic potential of induced iron depletion using iron chelators in Covid-19
title_full Therapeutic potential of induced iron depletion using iron chelators in Covid-19
title_fullStr Therapeutic potential of induced iron depletion using iron chelators in Covid-19
title_full_unstemmed Therapeutic potential of induced iron depletion using iron chelators in Covid-19
title_short Therapeutic potential of induced iron depletion using iron chelators in Covid-19
title_sort therapeutic potential of induced iron depletion using iron chelators in covid-19
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666385/
https://www.ncbi.nlm.nih.gov/pubmed/34924800
http://dx.doi.org/10.1016/j.sjbs.2021.11.061
work_keys_str_mv AT poonkuzhinaseefpunnoth therapeuticpotentialofinducedirondepletionusingironchelatorsincovid19
AT elayadethmeethalmuhammed therapeuticpotentialofinducedirondepletionusingironchelatorsincovid19
AT mohammedsalimkt therapeuticpotentialofinducedirondepletionusingironchelatorsincovid19
AT anjanaa therapeuticpotentialofinducedirondepletionusingironchelatorsincovid19
AT muhasc therapeuticpotentialofinducedirondepletionusingironchelatorsincovid19
AT abdulvajidk therapeuticpotentialofinducedirondepletionusingironchelatorsincovid19
AT saheerkuruniyanmohamed therapeuticpotentialofinducedirondepletionusingironchelatorsincovid19